ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Phase 1
Recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: ProAgio Dose ExpansionDrug: ProAgio Dose Levels (DL) 1,2,3,4
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- ProDa BioTech, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT06460298
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1
Recruiting
- Conditions
- Pancreatic Ductal Carcinoma
- Interventions
- Drug: ProAgio Dose Levels (DL) 1,2,3,4
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- ProDa BioTech, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT06182072
- Locations
- 🇺🇸
O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, United States
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
Phase 1
Active, not recruiting
- Conditions
- Advanced Pancreatic CancerSolid Tumor Malignancies
- Interventions
- Drug: ProAgio Dose Levels (DL) 1,2,3Drug: ProAgio Dose Levels (DL) 4,5,6Drug: ProAgio Dose Levels 4a,5a,6a
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- ProDa BioTech, LLC
- Target Recruit Count
- 58
- Registration Number
- NCT05085548
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath